BACE1 Inhibitor Lanabecestat (AZD3293) in a Phase 1 Study of Healthy Japanese Subjects: Pharmacokinetics and Effects on Plasma and Cerebrospinal Fluid Aβ Peptides

No abstract is available for this paper.

• Publication year

  2017

• Venue

  Journal of clinical pharmacology

• Publication date

  2017-11-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1002/jcph.950PMID 28618005
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Stepping closer to treating Alzheimer’s disease patients with BACE1 inhibitor drugs

  2016cited by this paper
• AZD3293: A Novel, Orally Active BACE1 Inhibitor with High Potency and Permeability and Markedly Slow Off-Rate Kinetics

  2016cited by this paper
• AZD3293: Pharmacokinetic and Pharmacodynamic Effects in Healthy Subjects and Patients with Alzheimer’s Disease

  2016cited by this paper
• The Potent BACE1 Inhibitor LY2886721 Elicits Robust Central Aβ Pharmacodynamic Responses in Mice, Dogs, and Humans

  2015cited by this paper
• The evolution of amidine-based brain penetrant BACE1 inhibitors.

  2014cited by this paper
• Targeting the β secretase BACE1 for Alzheimer's disease therapy.

  2014cited by this paper
• Function, therapeutic potential and cell biology of BACE proteases: current status and future prospects

  2014cited by this paper
• β-secretase inhibitor; a promising novel therapeutic drug in Alzheimer’s disease

  2014cited by this paper
• BACE1 inhibitor drugs in clinical trials for Alzheimer’s disease

  2014cited by this paper
• The structural evolution of β-secretase inhibitors: a focus on the development of small-molecule inhibitors.

  2013cited by this paper
• Sustained peripheral depletion of amyloid-β with a novel form of neprilysin does not affect central levels of amyloid-β

  2013cited by this paper
• Molecular Pathology of Alzheimer's Disease

  2013cited by this paper
• Oral Sessions: O1-06: Therapeutics: Clinical Trials I P139 O1-06-04 EFFICACY OF SOLANEZUMAB IN PATIENTS WITH MILD OR MODERATE ALZHEIMER’S DISEASE: POOLED ANALYSES FINDINGS FROM TWO PHASE III STUDIES

  2013cited by this paper
• P1‐225: A study to evaluate the pharmacokinetics and pharmacodynamics of single and multiple oral doses of the novel BACE inhibitor MK‐8931 in Japanese subjects

  2012cited by this paper
• A mutation in APP protects against Alzheimer’s disease and age-related cognitive decline

  2012cited by this paper
• The amyloid cascade hypothesis for Alzheimer's disease: an appraisal for the development of therapeutics

  2011cited by this paper
• Drugs for Alzheimer's disease: are they effective?

  2010cited by this paper
• The Amyloid Hypothesis of Alzheimer ’ s Disease : Progress and Problems on the Road to Therapeutics

  2009cited by this paper
• Partial Reduction of BACE1 Has Dramatic Effects on Alzheimer Plaque and Synaptic Pathology in APP Transgenic Mice*

  2007cited by this paper
• BACE1, a Major Determinant of Selective Vulnerability of the Brain to Amyloid-β Amyloidogenesis, is Essential for Cognitive, Emotional, and Synaptic Functions

  2005cited by this paper
• Differences in Drug Pharmacokinetics Between East Asians and Caucasians and the Role of Genetic Polymorphisms

  2004cited by this paper
• The Amyloid Hypothesis of Alzheimer's Disease: Progress and Problems on the Road to Therapeutics

  2002cited by this paper
• Age-dependent changes in brain, CSF, and plasma amyloid (beta) protein in the Tg2576 transgenic mouse model of Alzheimer's disease.

  2001cited by this paper
• BACE knockout mice are healthy despite lacking the primary beta-secretase activity in brain: implications for Alzheimer's disease therapeutics.

  2001cited by this paper
• Age-Dependent Changes in Brain, CSF, and Plasma Amyloid β Protein in the Tg2576 Transgenic Mouse Model of Alzheimer's Disease

  2001cited by this paper
• Pharmacogenetics and psychopharmacotherapy

  2000cited by this paper
• The Mini-International Neuropsychiatric Interview (M.I.N.I.): the development and validation of a structured diagnostic psychiatric interview for DSM-IV and ICD-10.

  1998cited by this paper
• An increased percentage of long amyloid beta protein secreted by familial amyloid beta protein precursor (beta APP717) mutants.

  1994cited by this paper
• Release of excess amyloid beta protein from a mutant amyloid beta protein precursor.

  1993cited by this paper
• Mutation of the beta-amyloid precursor protein in familial Alzheimer's disease increases beta-protein production.

  1992cited by this paper
• A pathogenic mutation for probable Alzheimer's disease in the APP gene at the N–terminus of β–amyloid

  1992cited by this paper
• Mutation of the β-amyloid precursor protein in familial Alzheimer's disease increases β-protein production

  1992cited by this paper
• The molecular pathology of Alzheimer's disease.

  1991cited by this paper

• A Novel RAGE Modulator Induces Soluble RAGE to Reduce BACE1 Expression in Alzheimer's Disease

  2025cites this paper
• Developing Novel Beta-Secretase Inhibitors in a Computer Model as a Possible Treatment for Alzheimer's Disease

  2025cites this paper
• Key Chemotypes for the Rational Design of Dual AChE/BACE-1 Inhibitors.

  2025cites this paper
• "Unveiling Alzheimer's Disease (1901-2025): Historical Insights, Global Burden, Biological Mechanisms, Diagnostics, And Therapeutic Strategies".

  2025cites this paper
• Amyloid-beta metabolism in age-related neurocardiovascular diseases

  2024cites this paper
• The Interplay of Protein Aggregation, Genetics, and Oxidative Stress in Alzheimer’s Disease: Role for Natural Antioxidants and Immunotherapeutics

  2024cites this paper
• Coptisine reverses Alzheimer’s disease by targeting cholinergic and amyloidogenic pathways

  2024cites this paper
• Navigating the Alzheimer's Treatment Landscape: Unraveling Amyloid-Beta Complexities and Pioneering Precision Medicine Approaches.

  2024cites this paper
• Recent advances in Alzheimer’s disease therapy: clinical trials and literature review of novel enzyme inhibitors targeting amyloid precursor protein

  2024cites this paper
• Disease-modifying therapies for Alzheimer's disease: clinical trial progress and opportunity.

  2024cites this paper
• Advances in Alzheimer’s disease’s pharmacological treatment

  2023cites this paper
• Oxygen metabolism abnormality and Alzheimer's disease: An update

  2023cites this paper
• Amyloid β-based therapy for Alzheimer’s disease: challenges, successes and future

  2023cites this paper
• Efficacy of Beta-Secretase-1 Enzyme Inhibitors in Alzheimer's Disease

  2023cites this paper
• The association of subjective sleep characteristics and plasma biomarkers of Alzheimer’s disease pathology in older cognitively unimpaired adults with higher amyloid-β burden

  2023cites this paper
• Advancement in Analytical Techniques for Determining the Activity of β-Site Amyloid Precursor Protein Cleaving Enzyme 1

  2022cites this paper
• BACE1 Inhibitors for Alzheimer’s Disease: The Past, Present and Any Future?

  2022cites this paper
• Omics-based biomarkers discovery for Alzheimer's disease

  2022cites this paper
• Design, Synthesis, and Biological Evaluation of Notopterol Derivatives as Triple Inhibitors of AChE/BACE1/GSK3β for the Treatment of Alzheimer’s Disease

  2022cites this paper
• Amyloid- β Oligomers: Multiple Moving Targets

  2022cites this paper
• Insights for Alzheimer's disease pharmacotherapy and current clinical trials.

  2022cites this paper
• Role of Natural Compounds and Target Enzymes in the Treatment of Alzheimer’s Disease

  2022cites this paper
• Alzheimer's Disease and β-Secretase Inhibition: An Update With a Focus on Computer-Aided Inhibitor Design.

  2021cites this paper
• The Swedish dilemma - the almost exclusive use of APPswe-based mouse models impedes adequate evaluation of alternative β-secretases.

  2021cites this paper
• Molecular and Therapeutic Targets for Amyloid-beta Plaques in Alzheimer’s Disease: A Review Study

  2021cites this paper
• Drug discovery and development: An overview of modern methods and principles

  2021cites this paper
• Post-Translational Modifications of BACE1 in Alzheimer's Disease

  2021cites this paper
• Targeting for Success: Demonstrating Proof-of-Concept with Mechanistic Early Phase Clinical Pharmacology Studies for Disease-Modification in Neurodegenerative Disorders

  2021cites this paper
• Nanotechnological approaches for targeting amyloid-β aggregation with potential for neurodegenerative disease therapy and diagnosis.

  2021cites this paper
• Nucleic acid liquid biopsies in Alzheimer's disease: current state, challenges, and opportunities

  2021cites this paper
• Multiple proteases are involved in mesothelin shedding by cancer cells

  2020cites this paper
• Assessment of Transporter Polymorphisms as a Factor in a BCRP Drug Interaction Study With Lanabecestat

  2020cites this paper
• Chronological review of potential disease modifying therapeutic strategies for Alzheimer's disease.

  2020cites this paper
• Computational screening of promising beta-secretase 1 inhibitors through multi-step molecular docking and molecular dynamics simulations - Pharmacoinformatics approach

  2020cites this paper
• Is It the Twilight of BACE1 Inhibitors?

  2020cites this paper
• Effects of Gentiana delavayi Flower Extract on APP Processing in APP/PS1 CHO Cells.

  2020cites this paper
• A Systematic Review of Current Progresses in The Nucleic Acid-Based Therapies for Neurodegeneration with Implications for Alzheimer's disease.

  2020cites this paper
• Partial reduction of amyloid β production by β-secretase inhibitors does not decrease synaptic transmission

  2020cites this paper
• Targeting Amyloidogenic Processing of APP in Alzheimer’s Disease

  2020cites this paper
• Apolipoprotein J in Alzheimer's Disease: Shedding Light on Its Role with Cell Signaling Pathway Perspective and Possible Therapeutic Approaches.

  2020cites this paper
• Multiple proteases are involved in mesothelin shedding by cancer cells

  2020cites this paper
• A Close Look at BACE1 Inhibitors for Alzheimer’s Disease Treatment

  2019cites this paper
• A critical appraisal of amyloid-β-targeting therapies for Alzheimer disease

  2019cites this paper
• Design, synthesis and evaluation of 2-amino-imidazol-4-one derivatives as potent β-site amyloid precursor protein cleaving enzyme 1 (BACE-1) inhibitors.

  2019cites this paper
• Emerging Developments in Targeting Proteotoxicity in Neurodegenerative Diseases

  2019cites this paper
• Multiple BACE1 inhibitors abnormally increase the BACE1 protein level in neurons by prolonging its half‐life

  2019cites this paper
• Current and Prospective Treatments for Alzheimer's Disease (and Other Neurodegenerative Diseases)

  2019cites this paper
• Challenges in the treatment of Alzheimer’s disease: recent progress and treatment strategies of pharmaceuticals targeting notable pathological factors

  2019cites this paper
• Therapeutic Strategies Targeting Amyloid-β in Alzheimer's Disease.

  2019cites this paper
• The Potential Markers of Circulating microRNAs and long non-coding RNAs in Alzheimer's Disease

  2019cites this paper
• AN UPDATE ON TREATMENT OF ALZHEIMER DISEASE- A LITERATURE REVIEW

  2018cites this paper
• Alzheimer's Disease: Advances in Drug Development.

  2018cites this paper
• BACE inhibitors in clinical development for the treatment of Alzheimer’s disease

  2018cites this paper
• Axonal organization defects in the hippocampus of adult conditional BACE1 knockout mice

  2018cites this paper
• Roasted Coffee Reduces &bgr;‐Amyloid Production by Increasing Proteasomal &bgr;‐Secretase Degradation in Human Neuroblastoma SH‐SY5Y Cells

  2018cites this paper
• Towards frailty biomarkers: Candidates from genes and pathways regulated in aging and age-related diseases.

  2018cites this paper
• BACE1 Function and Inhibition: Implications of Intervention in the Amyloid Pathway of Alzheimer’s Disease Pathology

  2017cites this paper
• BACE-1 Enzyme: A Promising Target for Alzheimer’s Disease

  year unknowncites this paper